Over 30% Covaxin takers suffered from health issues after 1 year: Report
Thursday, 16 May 2024
A study from BHU analyzing the lasting impacts of Bharat Biotech's Covaxin found nearly a third of recipients reported adverse events of special interest (AESI). Among 926 participants, viral upper respiratory tract infections were prevalent. Serious AESI like stroke and Guillain-Barre syndrome were noted in one percent of cases.
|
||||
|
|
||||
You Might Like💡 newsR Knowledge: Other News Mentions |
||||
